208 related articles for article (PubMed ID: 20850172)
1. Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography.
Hacquard M; Perrin J; Lelievre N; Vigneron C; Lecompte T
Thromb Res; 2011 Jan; 127(1):29-34. PubMed ID: 20850172
[TBL] [Abstract][Full Text] [Related]
2. Interindividual variability of in vitro response to anticoagulants.
Samama MM
Thromb Res; 2011 Jan; 127(1):1. PubMed ID: 21075429
[No Abstract] [Full Text] [Related]
3. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
4. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
[TBL] [Abstract][Full Text] [Related]
5. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
Rezaie AR
Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
[TBL] [Abstract][Full Text] [Related]
6. The reduced anticoagulant effect of fondaparinux at low antithrombin levels.
Dempfle CE; Eichner J; Suvajac N; Ahmad-Nejad P; Neumaier M; Borggrefe M
Anesth Analg; 2009 Sep; 109(3):712-6. PubMed ID: 19690236
[TBL] [Abstract][Full Text] [Related]
7. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
8. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
[TBL] [Abstract][Full Text] [Related]
9. Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma.
Dempfle CE; Zharkowa U; Elmas E; Ahmad-Nejad P; Neumaier M; Borggrefe M
Thromb Haemost; 2009 Nov; 102(5):1001-6. PubMed ID: 19888540
[TBL] [Abstract][Full Text] [Related]
10. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
Peyrou V; Béguin S; Boneu B; Hemker HC
Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
[TBL] [Abstract][Full Text] [Related]
11. New antithrombin-based anticoagulants.
Desai UR
Med Res Rev; 2004 Mar; 24(2):151-81. PubMed ID: 14705167
[TBL] [Abstract][Full Text] [Related]
12. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
13. Facts and artefacts of coagulation assays for factor Xa inhibitors.
Haas S
Thromb Haemost; 2010 Apr; 103(4):686-8. PubMed ID: 20174751
[No Abstract] [Full Text] [Related]
14. Mode of action of heparin and related drugs.
Hemker HC; Beguin S
Semin Thromb Hemost; 1991; 17 Suppl 1():29-34. PubMed ID: 1648791
[No Abstract] [Full Text] [Related]
15. Heparin and low-molecular-weight heparin.
Gray E; Mulloy B; Barrowcliffe TW
Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
17. Automated assay for fondaparinux (Arixtra) on the Dade Behring BCS XP.
Sanfelippo MJ; Tillema VB
Am J Clin Pathol; 2009 Oct; 132(4):608-12. PubMed ID: 19762539
[TBL] [Abstract][Full Text] [Related]
18. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
[TBL] [Abstract][Full Text] [Related]
19. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
Harenberg J; Giese C; Hagedorn A; Traeger I; Fenyvesi T
Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847
[TBL] [Abstract][Full Text] [Related]
20. The importance of anti-factor Xa and antithrombin activities of low molecular weight heparins.
Lane DA; Ryan K
J Lab Clin Med; 1990 Aug; 116(2):269-70. PubMed ID: 2394942
[No Abstract] [Full Text] [Related]
[Next] [New Search]